Long-term effectiveness of an intervention to enhance mirabegron use revision and its deprescribing: 36-month follow-up of a quasi-experimental trial in primary care

References

• Irwin DE, Abrams P, Milsom I, et al. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. 2008;101(11):1381–1387.
   PubMed Web of Science ®Google Scholar
• Martínez Agulló E, Ruiz Cerdá JL, Gómez Pérez L, et al. Prevalencia de incontinencia urinaria y vejiga hiperactiva en la población española: resultados del estudio EPICC [Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: results of the EPICC study]. Actas Urol Esp. 2009;33(2):159–166.
   PubMedGoogle Scholar
• Burkhard FC, Bosch JLHR, Cruz F, et al. EAU guidelines on urinary incontinence. 2018. [cited 2020 Jun 15]. https://uroweb.org/guideline/urinary-incontinence/.
   Google Scholar
• Urinary incontinence and pelvic organ prolapse in women: management (NG123). National Institute for Health and Care Excellence (NICE). 2019. [cited 2020 Jun 30]. https://www.nice.org.uk/guidance/ng123.
   Google Scholar
• Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350(8):786–799.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cruz F, Cardozo L, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77(1):119–128.
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014;9(4):433–448.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Betmiga: summary of product characteristics. 2013. Last updated on 2020. [cited 2020 Sep 20]. https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga#product-information-section.
   Google Scholar
• Catalan Health Service. Mirabegron (Betmiga). [Comparative evaluation report and opinion. Pharmacotherapeutic Harmonization Program in the Primary and Community Health Service of the Catalan Health Department (In Catalan). 2014. [cited 2020 Jun 1]. http://catsalut.gencat.cat/ca/proveidors-professionals/farmaciamedicaments/programa-harmonitzacio-farmacoterapeutica/.
   Google Scholar
• Batista JE, Kölbl H, Herschorn S, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7(4):167–179.
   PubMed Web of Science ®Google Scholar
• Fernández-Liz E, Vivo Tristante P, Aranzana Martínez A, et al. Effectiveness of an intervention to optimise the use of mirabegron for overactive bladder: a quasi-experimental study in primary care. Br J Gen Pract. 2018;68(677):e852–e859.
   PubMed Web of Science ®Google Scholar
• Fernández-Liz E, Modamio P, Catalán A, et al. Identifying how age and gender influence prescription drug use in a primary health care environment in Catalonia. Br J Clin Pharmacol. 2008;65(3):407–417.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejón A, et al. Estudio observacional retrospectivo multicéntrico de pacientes con vejiga hiperactiva en tratamiento con mirabegrón y oxibutinina en condiciones de práctica clínica habitual. [A retrospective, observational and multicentre study on patients with hyperactive bladder on treatment with mirabegron and oxybutinine under usual clinical practice conditions]. Semergen. 2017;43(4):277–288. Spanish.
   PubMedGoogle Scholar
• Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–834.
   PubMed Web of Science ®Google Scholar
• Bala SS, Jamieson HA, Nishtala PS. Factors associated with inappropriate prescribing among older adults with complex care needs who have undergone the interRAI assessment. Curr Med Res Opin. 2019;35(5):917–923.
   PubMed Web of Science ®Google Scholar
• Catalan Health Service. Treatment of urinary incontinence. Àrea Integral de Salut Barcelona Nord. [In Catalan]. CatSalut, 2015. [cited 2020 Oct 30]. http://salutintegralbcn.gencat.cat/ca/Arees_Integrals_de_Salut/ais-barcelona-nord/.
   Google Scholar
• Reeve E, Shakib S, Hendrix I, et al. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014; 78(4):738–747.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC, Lyles C, Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94(3):361–366.
   PubMed Web of Science ®Google Scholar
• Watkins C, Timm A, Gooberman-Hill R, et al. Factors affecting feasibility and acceptability of a practice-based educational intervention to support evidence-based prescribing: a qualitative study. Fam Pract. 2004;21(6):661–669.
   PubMed Web of Science ®Google Scholar
• Lim WY, Hss AS, Ng LM, et al. The impact of a prescription review and prescriber feedback system on prescribing practices in primary care clinics: a cluster randomised trial. BMC Fam Pract. 2018;19(1):120.
   PubMedGoogle Scholar
• Heintjes EM, Bezemer ID, Prieto-Alhambra D, et al. Evaluating the effectiveness of an additional risk minimization measure to reduce the risk of prescribing mirabegron to patients with severe uncontrolled hypertension in four European countries. Clin Epidemiol. 2020;12:423–433.
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–1774.
   PubMed Web of Science ®Google Scholar
• Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191(4):1003–1008.
   PubMed Web of Science ®Google Scholar
• Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9(9-10):343–350.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejón A, et al. Persistencia y medicación concomitante en pacientes con vejiga hiperactiva tratados con antimuscarínicos en atención primaria: estudio de base observacional. Actas Urol Esp. 2016;40(2):96–101.
   PubMedGoogle Scholar
• Kinjo M, Sekiguchi Y, Yoshimura Y, et al. Long-term persistence with mirabegron versus solifenacin in women with overactive bladder: prospective, randomized trial. Lower Urinary Tract Symptoms. 2018;10(2):148–152.
   PubMed Web of Science ®Google Scholar
• Moriarty F, Razzaque S, McDowell R, et al. Prescribing variation in general practices in england following a direct healthcare professional communication on mirabegron. JCM. 2018;7(10):320.
   Google Scholar
• Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–399.
   PubMed Web of Science ®Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–1282.
   PubMed Web of Science ®Google Scholar
• Jundt K, Schreyer K, Friese K, et al. Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet. 2011;284(3):663–666.
   PubMed Web of Science ®Google Scholar
• Sebastianelli A, Russo GI, Kaplan SA, et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: comparison with placebo and tolterodine. Int J Urol. 2018;25(3):196–205.
   PubMed Web of Science ®Google Scholar
• Maskell K, McDonald P, Paudyal P. Effectiveness of health education materials in general practice waiting rooms: a cross-sectional study. Br J Gen Pract. 2018;68(677):e869–e876.
   PubMed Web of Science ®Google Scholar
• Espuña Pons M, Rebollo Álvarez P, Puig Clota M. Validación de la versión española del International Consultation on Incontinence Questionnaire-Short Form. Un cuestionario para evaluar la incontinencia urinaria [Validation of the Spanish version of the International Consultation on Incontinence Questionnaire-Short Form. A questionnaire for assessing the urinary incontinence]. Med Clin (Barc). 2004;122(8):288–292. Spanish.
   PubMed Web of Science ®Google Scholar
• Freeman R, Foley S, Rosa Arias J, et al. Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Curr Med Res Opin. 2018;34(5):785–793.
   PubMed Web of Science ®Google Scholar
• Carlson KV, Rovner ES, Nair KV, et al. Factors associated with improvements in patient-reported outcomes during mirabegron or antimuscarinic treatment of overactive bladder syndrome: a registry study (PERSPECTIVE). Adv Ther. 2019;36(8):1906–1921.
   PubMed Web of Science ®Google Scholar
• Cano-Serral G, Azlor E, Rodríguez-Sanz M, et al. Socioeconomic inequalities in mortality in Barcelona: a study based on census tracts (MEDEA Project). Health Place. 2009;15(1):186–192.
   PubMed Web of Science ®Google Scholar